Aeglea Bio Therapeutics Stock Price, News & Analysis (NASDAQ:AGLE)

$6.08 +0.06 (+1.00 %)
(As of 02/20/2018 10:19 AM ET)
Previous Close$6.08
Today's Range$6.05 - $6.16
52-Week Range$2.81 - $8.14
Volume57,500 shs
Average Volume82,792 shs
Market Capitalization$101.20 million
P/E Ratio-3.32
Dividend YieldN/A
Beta2.99

About Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics logoAeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935

Debt

Debt-to-Equity RatioN/A
Current Ratio12.22%
Quick Ratio12.22%

Price-To-Earnings

Trailing P/E Ratio-3.3224043715847
Forward P/E Ratio-3.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.63 million
Price / Sales21.85
Cash FlowN/A
Price / CashN/A
Book Value$4.69 per share
Price / Book1.30

Profitability

Trailing EPS($1.83)
Net Income$-21,690,000.00
Net Margins-527.99%
Return on Equity-44.05%
Return on Assets-41.00%

Miscellaneous

Employees30
Outstanding Shares16,640,000

Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions

What is Aeglea Bio Therapeutics' stock symbol?

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How were Aeglea Bio Therapeutics' earnings last quarter?

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.07. The biotechnology company had revenue of $1.26 million for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. View Aeglea Bio Therapeutics' Earnings History.

Who are some of Aeglea Bio Therapeutics' key competitors?

Who are Aeglea Bio Therapeutics' key executives?

Aeglea Bio Therapeutics' management team includes the folowing people:

  • Armen B Shanafelt Ph.D., Independent Chairman of the Board (Age 58)
  • Anthony G. Quinn M.D. Ph.D., Interim Chief Executive Officer, Director (Age 55)
  • George Georgiou Ph.D., Co-Founder, Director (Age 56)
  • Charles N. York II, Chief Financial Officer, Vice President (Age 39)
  • Henry L. Hebel, Vice President - Product Development (Age 44)
  • Scott W. Rowlinson, Vice President - Research (Age 48)
  • Joseph E. Tyler, Vice President - Manufacturing (Age 65)
  • Suzanne Bruhn, Director
  • Russell J. Cox, Independent Director (Age 54)
  • Sandesh Mahatme, Independent Director (Age 52)

When did Aeglea Bio Therapeutics IPO?

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Who owns Aeglea Bio Therapeutics stock?

Aeglea Bio Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (8.37%), PRUDENTIAL FINANCIAL INC (8.40%) and Renaissance Technologies LLC (0.19%). Company insiders that own Aeglea Bio Therapeutics stock include Anthony G Quinn, Anthony Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Institutional Ownership Trends for Aeglea Bio Therapeutics.

Who bought Aeglea Bio Therapeutics stock? Who is buying Aeglea Bio Therapeutics stock?

Aeglea Bio Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Jennison Associates LLC. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn, Anthony Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Insider Buying and Selling for Aeglea Bio Therapeutics.

How do I buy Aeglea Bio Therapeutics stock?

Shares of Aeglea Bio Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeglea Bio Therapeutics' stock price today?

One share of Aeglea Bio Therapeutics stock can currently be purchased for approximately $6.08.

How big of a company is Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics has a market capitalization of $101.20 million and generates $4.63 million in revenue each year. The biotechnology company earns $-21,690,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Aeglea Bio Therapeutics employs 30 workers across the globe.

How can I contact Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]


MarketBeat Community Rating for Aeglea Bio Therapeutics (AGLE)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aeglea Bio Therapeutics (NASDAQ:AGLE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$19.00
Price Target Upside: N/AN/AN/A224.23% upside

Aeglea Bio Therapeutics (NASDAQ:AGLE) Consensus Price Target History

Price Target History for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ:AGLE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2016BMO Capital MarketsReiterated RatingBuy$19.00N/AView Rating Details
5/9/2016Needham & Company LLCInitiated CoverageBuy$18.00N/AView Rating Details
5/2/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Aeglea Bio Therapeutics (NASDAQ:AGLE) Earnings History and Estimates Chart

Earnings by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ AGLE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.55)($0.48)$1.26 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.59)($0.47)$1.48 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.47)($0.47)$0.98 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.41)$1.25 millionViewN/AView Earnings Details
11/9/20169/30/2016($0.54)($0.47)$1.15 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.43)($0.46)$1.37 millionViewN/AView Earnings Details
5/19/2016Q1 2016($0.42)($7.10)$0.86 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aeglea Bio Therapeutics (NASDAQ:AGLE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.97 EPS
Next Year EPS Consensus Estimate: $-2 EPS

Dividends

Dividend History for Aeglea Bio Therapeutics (NASDAQ:AGLE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 47.04%
Insider Trades by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)
Institutional Ownership by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2017Anthony G QuinnCEOBuy8,288$4.96$41,108.4832,009View SEC Filing  
12/6/2017Anthony G QuinnCEOBuy4,888$4.92$24,048.9632,009View SEC Filing  
12/5/2017Charles N York IICFOBuy25,959$4.48$116,296.3210,828View SEC Filing  
12/4/2017Anthony G QuinnDirectorBuy7,956$4.98$39,620.8814,100View SEC Filing  
12/1/2017Anthony G QuinnDirectorBuy4,100$4.53$18,573.0014,100View SEC Filing  
12/1/2017Charles N York IICFOBuy6,500$4.59$29,835.0010,828View SEC Filing  
2/21/2017Orbimed Advisors LlcMajor ShareholderBuy109,300$5.16$563,988.00View SEC Filing  
4/12/2016Anthony QuinnDirectorBuy10,000$10.00$100,000.0010,000View SEC Filing  
4/12/2016Bioventures Ltd NovartisMajor ShareholderBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aeglea Bio Therapeutics (NASDAQ AGLE) News Headlines

Source:
DateHeadline
 Brokerages Set $24.00 Price Target for Aeglea Bio Therapeutics Inc (AGLE) Brokerages Set $24.00 Price Target for Aeglea Bio Therapeutics Inc (AGLE)
www.americanbankingnews.com - February 18 at 11:24 PM
Zacks: Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 10 at 3:12 PM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 7 at 11:42 PM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Average Rating of "Strong Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 21 at 5:26 AM
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism ConferenceAeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
finance.yahoo.com - January 18 at 7:02 PM
 Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Strong Buy" by Brokerages Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 5 at 7:24 PM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:11 PM
Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:02 PM
Head-To-Head Review: Aeglea Bio Therapeutics (AGLE) & Its CompetitorsHead-To-Head Review: Aeglea Bio Therapeutics (AGLE) & Its Competitors
www.americanbankingnews.com - December 15 at 5:30 AM
Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?
finance.yahoo.com - December 14 at 11:40 AM
Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Purchases 4,888 SharesAeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Purchases 4,888 Shares
www.americanbankingnews.com - December 8 at 11:16 PM
Aeglea Bio Therapeutics Inc (AGLE) CEO Buys $41,108.48 in StockAeglea Bio Therapeutics Inc (AGLE) CEO Buys $41,108.48 in Stock
www.americanbankingnews.com - December 8 at 8:52 PM
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare ConferenceAeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 8 at 11:41 AM
Analysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Post ($0.55) Earnings Per ShareAnalysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Post ($0.55) Earnings Per Share
www.americanbankingnews.com - December 6 at 2:46 PM
Aeglea Bio Therapeutics Inc (AGLE) CFO Charles N. York II Buys 6,500 SharesAeglea Bio Therapeutics Inc (AGLE) CFO Charles N. York II Buys 6,500 Shares
www.americanbankingnews.com - December 5 at 11:22 PM
Aeglea Bio Therapeutics Inc (AGLE) Director Purchases $18,573.00 in StockAeglea Bio Therapeutics Inc (AGLE) Director Purchases $18,573.00 in Stock
www.americanbankingnews.com - December 5 at 11:22 PM
Insider Buying: Aeglea Bio Therapeutics Inc (AGLE) Director Purchases 7,956 Shares of StockInsider Buying: Aeglea Bio Therapeutics Inc (AGLE) Director Purchases 7,956 Shares of Stock
www.americanbankingnews.com - December 5 at 11:22 PM
Charles N. York II Buys 25,959 Shares of Aeglea Bio Therapeutics Inc (AGLE) StockCharles N. York II Buys 25,959 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock
www.americanbankingnews.com - December 5 at 11:22 PM
Aeglea Bio Therapeutics (AGLE) versus Its Competitors Head-To-Head ComparisonAeglea Bio Therapeutics (AGLE) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - December 5 at 5:26 PM
Head to Head Survey: Aeglea Bio Therapeutics (AGLE) and The CompetitionHead to Head Survey: Aeglea Bio Therapeutics (AGLE) and The Competition
www.americanbankingnews.com - December 1 at 7:30 PM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 29, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 11:27 AM
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
finance.yahoo.com - November 29 at 11:27 AM
 Aeglea BioTherapeutics, Inc. (AGLE) Given Average Recommendation of "Strong Buy" by Analysts Aeglea BioTherapeutics, Inc. (AGLE) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - November 21 at 9:27 AM
-$0.55 EPS Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter-$0.55 EPS Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter
www.americanbankingnews.com - November 19 at 3:32 PM
Aeglea BioTherapeutics (AGLE) versus Its Rivals Critical ContrastAeglea BioTherapeutics (AGLE) versus Its Rivals Critical Contrast
www.americanbankingnews.com - November 19 at 1:16 PM
Reviewing Aeglea BioTherapeutics (AGLE) & Its CompetitorsReviewing Aeglea BioTherapeutics (AGLE) & Its Competitors
www.americanbankingnews.com - November 17 at 3:06 AM
Zacks: Aeglea BioTherapeutics, Inc. (AGLE) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Aeglea BioTherapeutics, Inc. (AGLE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 16 at 3:36 PM
Aeglea BioTherapeutics, Inc. (AGLE) Raised to Buy at Zacks Investment ResearchAeglea BioTherapeutics, Inc. (AGLE) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - November 10 at 9:20 PM
Aeglea BioTherapeutics, Inc. (AGLE) Posts  Earnings Results, Beats Estimates By $0.07 EPSAeglea BioTherapeutics, Inc. (AGLE) Posts Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsAeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 5:10 PM
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsAeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 5:10 PM
Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual MeetingAeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 2 at 8:56 PM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 2, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 3:52 PM
-$0.67 Earnings Per Share Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter-$0.67 Earnings Per Share Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter
www.americanbankingnews.com - October 30 at 1:20 AM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : October 17, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 4:31 PM
Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung CancerAeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
finance.yahoo.com - October 16 at 4:30 PM
Zacks: Analysts Anticipate Aeglea BioTherapeutics, Inc. (AGLE) to Post -$0.67 EPSZacks: Analysts Anticipate Aeglea BioTherapeutics, Inc. (AGLE) to Post -$0.67 EPS
www.americanbankingnews.com - October 11 at 12:06 AM
Aeglea BioTherapeutics (AGLE) versus Calithera Biosciences (CALA) Financial SurveyAeglea BioTherapeutics (AGLE) versus Calithera Biosciences (CALA) Financial Survey
www.americanbankingnews.com - September 25 at 4:34 PM
Topline data is expected in second half of 2018Topline data is expected in second half of 2018
globenewswire.com - September 6 at 8:33 PM
Aeglea BioTherapeutics (AGLE) Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for Treatment of Arginase 1 DeficiencyAeglea BioTherapeutics (AGLE) Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for Treatment of Arginase 1 Deficiency
www.streetinsider.com - September 6 at 8:33 PM
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 DeficiencyAeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
finance.yahoo.com - September 6 at 3:33 PM
-$0.67 EPS Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter-$0.67 EPS Expected for Aeglea BioTherapeutics, Inc. (AGLE) This Quarter
www.americanbankingnews.com - September 3 at 4:24 PM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : August 31, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 1:19 AM
Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 5:11 PM
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsAeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 8:53 PM
Aeglea BioTherapeutics, Inc. (AGLE) Set to Announce Earnings on MondayAeglea BioTherapeutics, Inc. (AGLE) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
Austin biotech company loses CEO as disease treatments work through regulatory processAustin biotech company loses CEO as disease treatments work through regulatory process
www.bizjournals.com - July 21 at 10:12 PM
Aeglea BioTherapeutics Announces Leadership ChangeAeglea BioTherapeutics Announces Leadership Change
finance.yahoo.com - July 20 at 4:33 PM
Aeglea Bio shares down 2% after CEO resignsAeglea Bio shares down 2% after CEO resigns
finance.yahoo.com - July 20 at 4:33 PM
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical OfficerAeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
finance.yahoo.com - July 10 at 8:21 PM

SEC Filings

Aeglea Bio Therapeutics (NASDAQ:AGLE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aeglea Bio Therapeutics (NASDAQ:AGLE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aeglea Bio Therapeutics (NASDAQ AGLE) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.